Advanced Virology

Does buying virus always win on cost? 🧪 In Part 3 of our series, we analyze a large adenoviral vector study (~40 mL). At scale, the gap narrows: in-house production ($40k–$80k) vs commercial ($25k–$50k). Read our full analysis: bit.ly/4sAgUXR

Make vs. buy in BSL-3? 🧪 Part 2 of our series breaks down the costs of an H5N1 neutralization study needing ~15 mL of virus. Containment overhead pushes in-house costs to $120k–$180k vs $30k–$50k to buy. Read the full analysis: bit.ly/47JXS80

Stop wasting lab bandwidth on custom viral constructs. Focus on discovery. 🧬 We deliver sequence-verified reporter virus stocks: 🔹 GFP, Luciferase & tags 🔹 Scalable HTS batches 🔹 High genetic fidelity 🔹 Assay design support Contact us to discuss your project!

Make vs. buy for virus stocks? 🧪 In Part 1 of our series, we look at the real costs of an influenza plaque assay validation. Fixed costs mean in-house production runs $50k–$90k vs $2k–$6k commercial. Read the full breakdown: bit.ly/4hVh5cL

Research Desk by Advanced Virology brings selected public research, funding and award records into a free personalized monthly briefing, with source links and a private profile for your preferences. Request your desk at bit.ly/4yP0CMx

Reporter viruses (GFP, NanoLuc®) enable high-throughput antiviral screening, but risk instability. 3 best practices: 1️⃣ Smaller reporters (NanoLuc) maintain stability 2️⃣ Cleavable fusions minimize attenuation 3️⃣ Sequence-verify to catch adaptation

Is serial passaging holding back your virology pipeline? Passaging has: Genetic Drift, Loss of Virulence, Batch Variability Reverse genetics changes the equation: Precision sequence, High reproducibility, Regulatory alignment How does your lab ensure virus stock consistency?

Did you know $28B is spent annually on irreproducible preclinical research? In Virology, serially passaging viruses introduces mutations that invalidate studies. The fix? Adopt plasmid-derived, sequence-verified stocks via reverse genetics. Know what’s in your vial. 🧪

For decades, the standard virology R&D model meant buying a small seed vial and expanding it in-house. In our latest blog, we explore why the industry is shifting from "Can we expand this virus ourselves?" to "Should we?" Read the full blog here: bit.ly/4ASXkdd

Is in-house virus expansion slowing your research? Variability between rounds creates hidden costs and inconsistent data. Don't let manufacturing bottleneck your discovery pipeline. Read more: bit.ly/4dTxpYW

Advanced Virology offers custom Bundibugyo Ebolavirus VLPs for assay development, vaccine research, diagnostics, and countermeasure evaluation. These non-replicating VLPs support filovirus workflows in BSL-2 labs. Read more: bit.ly/4dOSiDI

The integrity of your data starts with the integrity of your virus stock. 🧬 A single cell culture passage can fundamentally alter viral behavior — impacting virulence, reproducibility, and the validity of entire preclinical studies. Read the article: bit.ly/4doRXc8

Virology is evolving and so are the standards behind it. As research becomes more collaborative and global, the need for consistent, high-fidelity virus stocks has never been more critical. Read more: bit.ly/4cPMDOq

Reporter viruses are changing antiviral discovery. By converting viral replication into a measurable signal, researchers can rapidly screen compounds and track replication in real time. Learn how reporter virus systems accelerate antiviral research: bit.ly/46W9Rzf

Serial passaging has been foundational to virology for over a century—but the field is evolving. Read the full blog to explore why this shift matters and how it’s shaping the future of virology. bit.ly/4zjdnzr

At Advanced Virology, we support viral health solutions, from foundational research and product development to vaccines, diagnostics, and antivirals. Our team uses reverse genetics to engineer and manufacture viruses, powering critical testing and development.

At Advanced Virology, we provide high-fidelity genomic material that helps assay developers create more accurate, scalable, and regulatory-ready molecular tests. Here’s why quality matters—and how we help make it happen: bit.ly/478SvPk